Tandem Diabetes Care/$TNDM
1D1W1MYTD1Y5YMAX
Capital at risk
About Tandem Diabetes Care
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.
- Ticker
- $TNDM
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,500
- Headquarters
- San Diego, United States
- Website
- www.tandemdiabetes.com
TNDM Metrics
BasicAdvanced
$1.2B
-
-$0.93
1.54
-
Price and volume
Market cap
$1.2B
Beta
1.54
52-week high
$29.65
52-week low
$11.46
Average daily volume
1.9M
Financial strength
Current ratio
3.18
Quick ratio
2.443
Long term debt to equity
5.514
Total debt to equity
5.67
Interest coverage (TTM)
-4.89%
Profitability
EBITDA (TTM)
-25.033
Gross margin (TTM)
56.01%
Net profit margin (TTM)
-6.08%
Operating margin (TTM)
-4.13%
Effective tax rate (TTM)
-3.80%
Revenue per employee (TTM)
$420,000
Management effectiveness
Return on assets (TTM)
-2.65%
Return on equity (TTM)
-48.03%
Valuation
Price to revenue (TTM)
1.122
Price to book
9.13
Price to tangible book (TTM)
9.13
Price to free cash flow (TTM)
-18.92
Free cash flow yield (TTM)
-5.29%
Free cash flow per share (TTM)
-0.904
Growth
Revenue change (TTM)
3.96%
Earnings per share change (TTM)
-70.10%
3-year revenue growth (CAGR)
9.63%
10-year revenue growth (CAGR)
28.05%
3-year earnings per share growth (CAGR)
-35.65%
10-year earnings per share growth (CAGR)
-27.56%
What the Analysts think about TNDM
Analyst ratings (Buy, Hold, Sell) for Tandem Diabetes Care stock.
Analyst projections of the future price of Tandem Diabetes Care stock.
Bulls say / Bears say
Record Q1 2026 performance: shipments of over 29,000 pumps, sales of $247.2 M (up 5% YoY), and gross margin of 55% (up 480 bps) – the highest first-quarter margin in company history. (Business Wire)
Strong Q2 2026 results: sales of $254.6 M (up 6% YoY), gross margin expanded to 57% (up 460 bps), with the company reaffirming full-year guidance of $1.065 B–$1.085 B in revenue and 56%–57% gross margin. (SEC Filing)
Advancing product pipeline: submitted 510(k) for the Mobi tubeless patch pump, introduced Dexcom G7 sensor compatibility on t:slim X2 and Mobi, and launched Android compatibility for Mobi, bolstering competitive offerings. (SEC Filing)
Despite improved margins, Tandem remains unprofitable, reporting GAAP net losses of $20.4 M in Q1 2026 and $21.2 M in Q2 2026. (Business Wire) (SEC Filing)
Transition to a pay-as-you-go pharmacy model may delay revenue recognition and adds complexity, with guidance noting adoption and transition assumptions that could constrain near-term revenue and cash flow. (Business Wire) (Business Wire)
International growth lags domestic performance: Q1 2026 international sales grew just 3% YoY and declined 5% in constant currency, underscoring challenges in non-U.S. markets. (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
TNDM Financial Performance
Revenues and expenses
TNDM Earnings Performance
Company profitability
Upcoming events
No upcoming events
TNDM News
AllArticlesVideos
Funds containing TNDM
AllUSDEURGBP
Fund name | Fund size | $TNDM weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.14% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.14% |
iShares Healthcare Innovation£DRDR | £1B | 0.14% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.07% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.